ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2016
External quality assessment for the molecular detection of MERS-CoV in China.
Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Armored RNA technology as a clinical diagnostics tool for future pandemic preparedness.Journal of microbiology (Seoul, Korea) · 2026Review
- Virus-like particles derived from bacteriophage MS2 as antigen scaffolds and RNA protective shells.Nanomedicine (London, England) · 2024Review
- MICaFVi: A Novel Magnetic Immuno-Capture Flow Virometry Nano-Based Diagnostic Tool for Detection of Coronaviruses.Biosensors · 2023Article
- A novel assay based on DNA melting temperature for multiplexed identification of SARS-CoV-2 and influenza A/B viruses.Frontiers in microbiology · 2023Article
- One-plasmid double-expression system for preparation of MS2 virus-like particles packaging SARS-CoV-2 RNA.Frontiers in cellular and infection microbiology · 2023Article
- Middle East Respiratory Syndrome (MERS) Virus-Pathophysiological Axis and the Current Treatment Strategies.AAPS PharmSciTech · 2021Review
- Comparison of Seven Commercial Severe Acute Respiratory Syndrome Coronavirus 2 Nucleic Acid Detection Reagents with Pseudovirus as Quality Control Material.The Journal of molecular diagnostics : JMD · 2021Article
- External Quality Assessment for Molecular Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Clinical Laboratories.The Journal of molecular diagnostics : JMD · 2021Article
- Current and Future Point-of-Care Tests for Emerging and New Respiratory Viruses and Future Perspectives.Frontiers in cellular and infection microbiology · 2020Review
- An updated roadmap for MERS-CoV research and product development: focus on diagnostics.BMJ global health · 2019Article
- Proficiency testing for the detection of Middle East respiratory syndrome coronavirus demonstrates global capacity to detect Middle East respiratory syndrome coronavirus.Journal of medical virology · 2018Article
- Development and evaluation of armored RNA-based standards for quantification of BCR-ABL1Journal of clinical laboratory analysis · 2018Article
- The role of laboratory diagnostics in emerging viral infections: the example of the Middle East respiratory syndrome epidemic.Journal of microbiology (Seoul, Korea) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn May 2015, an imported case of Middle East respiratory syndrome coronavirus (MERS-CoV) infection occurred in China, so rapid and reliable diagnosis of suspected cases was necessary.
objectivesAn external quality assessment (EQA) program for the molecular detection of MERS-CoV was organized by the National Center for Clinical Laboratories (NCCL). STUDY
designMS2 virus-like particles (VLPs) encapsulating specific RNA sequences of MERS-CoV were prepared as positive specimens. The assessment panel, which comprised of three negative and seven positive samples with different concentrations of VLPs, was distributed to 56 laboratories from 16 provinces, municipalities, or autonomous regions for molecular detection.
resultsAmong the received data sets, three employed an in-house-developed real-time reverse-transcription polymerase chain reaction (rRT-PCR) assay and the others applied various commercial rRT-PCR kits. Overall, the majority of laboratories (46/56, 82.1%) could achieve 100% accuracy for MERS-CoV detection, but three laboratories (5.4%) still had room for improvement. Consequently, all negative samples were identified correctly, reaching 100% specificity. The false-negative rate was 3.1%, and most of the false-negative results were obtained from samples with relatively low concentration, indicating an urgent need to improve detection in weak-positive specimens.
conclusionsThe majority of participants possessed reliable diagnostic capacity for the detection of MERS-CoV. Moreover, EQA is indispensable because it can help enhance the diagnostic capability for the surveillance of MERS-CoV infections and allow comparison of the results among different laboratories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.